Immunis

Immunis, Inc. is a clinical-stage biotech company developing multi-active biologics to address age and disease-related immune dysregulation. Their lead product, IMM01-STEM, is in Phase 2 clinical trials for muscle loss and metabolic dysfunction, showing promising results in improving quality of life and physical function in elderly patients. The company leverages cutting-edge multi-active secretome technology.

Buy Funded Startups lists

Funding Round: Series A1

Funding Amount: $25M

Date: 11-Jan-2025

Investors: Remiges Ventures, Continuum Health Ventures, BOLD Capital Partners, LifeSpan Vision Ventures, JLS Fund

Markets: Biotechnology, Healthtech, Therapeutics

HQ: Irvine, California, United States

Founded: 2018

Website: https://immunisbiomedical.com

LinkedIn: https://www.linkedin.com/company/immunisbiomedical

Twitter:

Instagram: